Everett Harris & CO Abb Vie Inc. Transaction History

Everett Harris & CO

$8 Billion
Q3 2024

A detailed history of Everett Harris & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Everett Harris & CO holds 528,870 shares of ABBV stock, worth $94.1 Million. This represents 1.31% of its overall portfolio holdings.

Number of Shares

528,870

Previous 531,230 0.44%

Holding current value

$94.1 Million

Previous $91.1 Million 14.62%

% of portfolio

1.31%

Previous 1.17%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$163.84 - $199.33 $386,662 - $470,418	-2,360 Reduced 0.44%	528,870 $104 Million
Q2 2024 Aug 01, 2024	SELL	$154.79 - $180.76 $379,854 - $443,585	-2,454 Reduced 0.46%	531,230 $91.1 Million
Q1 2024 Apr 19, 2024	SELL	$159.82 - $182.1 $542,109 - $617,683	-3,392 Reduced 0.63%	533,684 $97.2 Million
Q4 2023 Jan 18, 2024	SELL	$137.6 - $154.97 $541,180 - $609,497	-3,933 Reduced 0.73%	537,076 $83.2 Million
Q3 2023 Oct 23, 2023	SELL	$133.59 - $154.65 $618,388 - $715,874	-4,629 Reduced 0.85%	541,009 $80.6 Million
Q2 2023 Jul 26, 2023	SELL	$132.51 - $164.9 $881,854 - $1.1 Million	-6,655 Reduced 1.2%	545,638 $73.5 Million
Q1 2023 Apr 24, 2023	SELL	$144.61 - $166.54 $152,563 - $175,699	-1,055 Reduced 0.19%	552,293 $88 Million
Q4 2022 Jan 20, 2023	SELL	$138.31 - $165.87 $278,003 - $333,398	-2,010 Reduced 0.36%	553,348 $0
Q3 2022 Oct 21, 2022	BUY	$134.21 - $153.93 $155,683 - $178,558	1,160 Added 0.21%	555,358 $74.5 Million
Q2 2022 Jul 22, 2022	SELL	$137.62 - $174.96 $877,052 - $1.12 Million	-6,373 Reduced 1.14%	554,198 $84.9 Million
Q1 2022 Apr 22, 2022	BUY	$131.98 - $163.75 $207,076 - $256,923	1,569 Added 0.28%	560,571 $90.9 Million
Q4 2021 Feb 02, 2022	BUY	$107.43 - $135.93 $4.84 Million - $6.13 Million	45,083 Added 8.77%	559,002 $75.7 Million
Q3 2021 Nov 03, 2021	BUY	$106.4 - $120.78 $1.76 Million - $2 Million	16,551 Added 3.33%	513,919 $55.4 Million
Q2 2021 Jul 29, 2021	BUY	$105.21 - $117.21 $2.41 Million - $2.68 Million	22,903 Added 4.83%	497,368 $56 Million
Q1 2021 May 13, 2021	BUY	$102.3 - $112.62 $7.16 Million - $7.88 Million	69,949 Added 17.29%	474,465 $51.3 Million
Q4 2020 Feb 04, 2021	BUY	$80.49 - $108.67 $3.14 Million - $4.24 Million	39,004 Added 10.67%	404,516 $43.3 Million
Q3 2020 Nov 03, 2020	BUY	$85.91 - $100.83 $13,659 - $16,031	159 Added 0.04%	365,512 $32 Million
Q2 2020 Jul 29, 2020	BUY	$73.37 - $98.18 $64,785 - $86,692	883 Added 0.24%	365,353 $35.9 Million
Q1 2020 Apr 29, 2020	BUY	$64.5 - $97.79 $643,194 - $975,161	9,972 Added 2.81%	364,470 $27.8 Million
Q4 2019 Jan 27, 2020	SELL	$72.13 - $90.25 $73,788 - $92,325	-1,023 Reduced 0.29%	354,498 $31.4 Million
Q3 2019 Nov 06, 2019	SELL	$62.98 - $75.72 $691,961 - $831,935	-10,987 Reduced 3.0%	355,521 $26.9 Million
Q2 2019 Aug 13, 2019	BUY	$65.7 - $83.98 $394,397 - $504,131	6,003 Added 1.67%	366,508 $26.7 Million
Q1 2019 May 13, 2019	SELL	$77.14 - $90.79 $155,051 - $182,487	-2,010 Reduced 0.55%	360,505 $29.1 Million
Q4 2018 Feb 13, 2019	SELL	$77.85 - $96.01 $1.25 Million - $1.54 Million	-16,001 Reduced 4.23%	362,515 $33.4 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $108,559 - $120,683	1,221 Added 0.32%	378,516 $35.8 Million
Q2 2018 Jul 27, 2018	BUY	$89.78 - $106.23 $11,491 - $13,597	128 Added 0.03%	377,295 $35 Million
Q1 2018 Apr 20, 2018	BUY	$92.01 - $123.21 $270,877 - $362,730	2,944 Added 0.79%	377,167 $35.7 Million
Q4 2017 Feb 01, 2018	SELL	$89.56 - $98.21 $55,079 - $60,399	-615 Reduced 0.16%	374,223 $36.2 Million
Q3 2017 Oct 11, 2017	BUY	$69.85 - $89.22 $26.2 Million - $33.4 Million	374,838	374,838 $33.3 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $315B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Everett Harris & CO , based on Form 13F filings with the SEC.

News

Stay updated on Everett Harris & CO with notifications on news.

Account

Everett Harris & CO Abb Vie Inc. Transaction History